Mesothelioma

P1, N=137, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Sep 2026 --> Jan 2027 | Trial primary completion date: Sep 2026 --> Jan 2027

P1, N=186, Recruiting, SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | Trial completion date: Jun 2030 --> Jan 2027 | Trial primary completion date: Jan 2030 --> Jan 2027

A total of six cycles of pemetrexed-cisplatin chemotherapy were given and elicited a partial response. The disease progressed and intraperitoneal bevacizumab-cisplatin therapy was administered, which was ineffective...Correct diagnosis is facilitated by an awareness of occupational exposure risk, such as that of asphalt exposure for the present case, and early histopathological evaluation. The prognosis for DPM remains poor despite multimodal therapy, and novel therapeutic strategies are needed.

P=N/A, N=70, Recruiting, University Hospital, Angers | Not yet recruiting --> Recruiting

According to the pharmacogenomic analysis from GDSC2 dataset, tumor cells that express higher DNA2 are more sensitive to Tozasertib, and Daporinad. DNA2 is at the core of several interrelated modules, including flap processing, telomerase extension, and cell-cycle progression, according to the enrichment study. These findings have suggested DNA2 as a therapeutic vulnerability in cancer, a context-dependent biomarker with implications for treatment response, prognosis, and immunity.

Furthermore, these cells produced anti-tumor effects in a novel 3D tumor spheroid model system established to evaluate the potency of reactive cells against tumors including pancreatic, cervical, and colorectal cancer and mesothelioma. These preclinical findings lay the groundwork for further exploration of MSLN as a potential immunotherapeutic target for T cells via the native T cell receptor.

Trop-2 was expressed in 20% of PMs, exclusively in epithelioid histology, associated with advanced disease and poor survival outcomes. These results support the prospective evaluation of Trop-2-targeted therapies in PM.

Importantly, these cells display a favorable safety profile, with minimal evidence of graft-versus-host disease, cytokine release syndrome, brain infiltration or neurotoxicity, and no detectable off-tumor effects. Collectively, these findings support the development of a clinically translatable, off-the-shelf CAR-NKT cell therapy for the treatment of MPM.

In sporadic meningiomas, BAP1 alterations are rare but define an aggressive molecular subset with poor outcomes. Here, we describe a patient with BAP1-TPDS and multifocal cranial meningiomas who experienced exceptional radiographic regression of her tumors while receiving dual immune checkpoint blockade for metastatic uveal melanoma.

One case harbored an ALK rearrangement, guiding effective targeted therapy with alectinib...Accurate histopathological assessment is essential to establish a correct diagnosis and guide appropriate therapy. A multidisciplinary approach remains the cornerstone of diagnostic precision in CUP cases.

Finally, this cascade triggers immunogenic cell death and orchestrates a chemokine storm, which is hypothesized to facilitate the conversion of the tumor microenvironment from an immune "cold" to a "hot" phenotype. Collectively, by integrating the physical disintegration of subcellular structures with immunological remodeling, TTFields may offer a hypothetical theoretical framework for overcoming therapeutic resistance in MPM.

P1, N=74, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027